First Time in Human Study of Protexia

Inclusion Criteria: * Healthy male or female volunteers aged 18 to 55 years * Willing to give written informed consent to participate in the study and to comply with all study requirements and procedures * In the opinion of the Investigator, in generally good health, based upon pre-study medical history, physical examination, electrocardiogram (ECG) and laboratory tests * Normal clinical chemistry, hematology and urinalysis results or clinically insignificant values during screening evaluations * Women of childbearing potential may be enrolled if one of the following criteria applies: * Using effective contraception (e.g., injectable, transdermal, vaginal ring, oral contraceptives, IUD or barrier methods) for at least three months prior to study entry, must have maintained a normal menstrual pattern for the 3 months prior to study entry and agree to continue contraception for the duration of their participation in the study. * Females using injectable, transdermal, vaginal ring, oral contraceptives or an IUD must agree to augment this with a barrier method for the duration of their participation in the study. * Is sexually abstinent * Is monogamous with a vasectomized partner * Is postmenopausal (i.e., no cycle for at least the previous 24 months and is of menopausal age (\> 45 years) * Has not had a menstrual cycle for 12 to 24 months and is of menopausal age as described above * Is surgically sterilized * Has had a total hysterectomy a minimum of 3 months prior to dosing on Day 1 * Females with a negative urine pregnancy test at study Screening and a negative serum pregnancy test on admission to the Phase I unit at Day -1 * Females in Group 3 will also require a negative serum pregnancy test on Day 71 prior to receiving Dose 2 * Sexually active male subjects may be enrolled if one of the following criteria applies: * Has had a vasectomy * Using condoms and whose partner is using an acceptable form of contraception (IUD, oral contraceptives, birth control patch or vaginal ring, injectable or implanted contraceptives, or tubal ligation \[surgical sterilization\]) for the duration of the study * Is sexually abstinent * Body Mass Index (BMI) 19 to 29, inclusive * Abstinence from alcohol for 24 hours prior to study drug administration until discharge from the Phase I unit on Day 4 Exclusion Criteria: * Inability to provide Informed Consent * Drug or alcohol abuse requiring treatment within 12 months of study screening * Positive drug result at time of study screening or positive alcohol result at Day -1 (and Day 71 for Group 3 subjects) * Use of cholinesterase inhibitors within 21 days of dosing * Receipt of fresh frozen plasma within three months of study screening * Allergy to milk or milk derived products * History of allergic reaction to procainamide or to its metabolite, p-aminobenzoic acid * Diagnosis of myasthenia gravis * Participation in any trial of an investigational agent within 30 days of study screening * Previous receipt of any investigational BChE product * Clinically significant medical or psychiatric condition that, in the opinion of the Investigator, may impair study participation * ECG with evidence of clinically significant conduction abnormalities or active ischemia at time of study screening * Donation of one or more pints of blood within 30 days prior to study screening * Known serum positivity for human immunodeficiency virus (HIV) antibodies, hepatitis B or hepatitis C * Extensive tattooing which would preclude adequate assessment at the injection site(s) * Females who are pregnant and/or breast feeding * Use of systemic immunosuppressive agents, such as used to treat Alzheimer's Disease, within 3 months of dosing * Use of dietary or herbal supplements within 3 months of dosing